Cefdiren200 mg

Cefdiren is a third-generation oral cephalosporin antibiotic. Its approved and evidence-supported indications include:

• Community-acquired pneumonia (mild to moderate) caused by susceptible strains of Streptococcus pneumoniae, Haemophilus influenzae, or Haemophilus parainfluenzae — an established, FDA-approved indication.
• Acute bacterial exacerbation of chronic bronchitis caused by susceptible organisms — an established indication.
• Pharyngitis and tonsillitis caused by Streptococcus pyogenes — an established indication, used as an alternative when penicillin is not suitable.
• Uncomplicated skin and skin-structure infections caused by Staphylococcus aureus (methicillin-susceptible) or Streptococcus pyogenes — an established indication.

Cefdiren is not effective against methicillin-resistant Staphylococcus aureus (MRSA) or atypical respiratory pathogens (e.g., Mycoplasma, Chlamydophila), and should be reserved for infections due to confirmed or strongly suspected susceptible bacteria to reduce the risk of resistance.

Each film-coated tablet contains Cefditoren pivoxil, a prodrug ester of cefditoren, equivalent to 200 mg or 400 mg of cefditoren base. The pivoxil ester is hydrolyzed during absorption, releasing pivalic acid, which can affect carnitine levels (see Precautions and Warnings). Tablets also contain excipients that may include sodium caseinate, a milk protein.

Cefdiren is a third-generation (extended-spectrum) oral cephalosporin antibiotic administered as the prodrug Cefdiren pivoxil. It is bactericidal, acting by inhibiting bacterial cell wall synthesis. Cefdiren has activity against a range of Gram-positive and Gram-negative organisms commonly implicated in respiratory tract and skin infections, and is formulated as an oral film-coated tablet for outpatient treatment of susceptible bacterial infections.

Cefdiren belongs to the class of third-generation cephalosporin antibiotics (oral extended-spectrum cephalosporins), within the broader beta-lactam antibiotic class.

Cefditoren exerts its antibacterial effect by binding to penicillin-binding proteins (PBPs), which are essential enzymes involved in the synthesis of the bacterial cell wall. This binding inhibits the final transpeptidation step of peptidoglycan synthesis, leading to cell wall instability and bacterial lysis, making Cefditoren bactericidal.

Cefditoren is administered as the inactive prodrug cefditoren pivoxil, which is hydrolyzed by esterases in the intestinal mucosa during absorption to release active cefditoren and pivalate. Absorption is enhanced by food, so Cefditoren should be taken with meals. It is minimally metabolized, is largely excreted unchanged by the kidneys, and does not significantly inhibit or induce cytochrome P450 enzymes.

Cefdiren tablets should be taken orally with food to enhance absorption. Swallow tablets whole with water; do not crush or chew. Doses should be spaced evenly (approximately every 12 hours) and the full prescribed course completed.

Cefdiren has the following clinically significant drug interactions:

• Antacids (aluminum/magnesium hydroxide): Concurrent use reduces peak plasma concentration of Cefdiren by approximately 14%; avoid simultaneous administration when possible.
• H2-receptor antagonists (e.g., famotidine): Reduce absorption of Cefdiren, decreasing peak concentration by approximately 27%; concurrent use should be avoided or timed carefully.
• Probenecid: Inhibits renal tubular secretion of Cefdiren, increasing plasma concentrations of Cefdiren by approximately 50%; concurrent use may require monitoring for adverse effects.
• Carnitine-lowering agents or products (e.g., valproic acid, pivalate-containing drugs): Additive risk of reduced carnitine levels with prolonged concurrent use of Cefdiren; see Precautions and Warnings.

Cefdiren does not significantly interact with oral contraceptives or warfarin based on available data, but routine monitoring is still advisable when combining with anticoagulants.

Common side effects of Cefdiren (occurring in more than 1% of patients) include:

• Diarrhea (most common, up to 15% of patients)
• Nausea
• Headache
• Vaginal fungal infection (vulvovaginal candidiasis) in female patients
• Abdominal pain
• Dyspepsia

Less common but clinically important effects include:

• Hypersensitivity reactions (rash, urticaria; rarely anaphylaxis)
• Clostridioides difficile-associated diarrhea and colitis, which can range from mild to life-threatening and may occur during or after treatment with Cefdiren
• Reduced serum carnitine levels with prolonged use (see Precautions and Warnings)
• Elevated liver enzymes (transient)

Patients should seek medical attention promptly for severe or persistent diarrhea, signs of allergic reaction, or unusual bruising/bleeding while taking Cefdiren.

Pregnancy: Animal reproduction studies with Cefdiren have not shown evidence of harm to the fetus; however, adequate and well-controlled studies in pregnant women are lacking. Cefdiren should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Consult a physician before use during pregnancy.

Lactation: It is not known whether Cefdiren is excreted in human breast milk. Because many cephalosporins are excreted in breast milk in small amounts, caution is advised and a physician should be consulted before using Cefdiren while breastfeeding, weighing the benefits of treatment against potential effects on the nursing infant (such as diarrhea or diaper rash from altered gut flora).

Carnitine Depletion

Prolonged or repeated use of Cefdiren can substantially reduce serum carnitine levels (reported reductions of up to 60% with extended dosing), because the pivalate moiety released during absorption is conjugated with carnitine and excreted. Cefdiren is therefore not recommended for prolonged courses of therapy, and should be used cautiously, with monitoring where feasible, in patients with pre-existing carnitine deficiency risk factors.

Hypersensitivity and Cross-Reactivity

Patients with a history of penicillin allergy may have partial cross-reactivity with Cefdiren and other cephalosporins; use with caution and monitor closely in such patients. Discontinue immediately if signs of a severe allergic reaction occur.

Clostridioides difficile-Associated Diarrhea

Cefdiren, like other broad-spectrum antibiotics, can permit overgrowth of C. difficile. Evaluate patients who develop diarrhea during or after treatment.

Renal Impairment

Dose adjustment of Cefdiren is required in moderate-to-severe renal impairment (see Dosage and Administration).

Antibiotic Stewardship

Take Cefdiren exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice. Using Cefdiren for viral infections (e.g., common cold) or misuse can promote drug-resistant bacteria.

Information on Cefdiren overdose in humans is limited. Manifestations of overdose may include exaggerated side effects such as nausea, vomiting, diarrhea, or abdominal pain. In case of suspected overdose of Cefdiren, seek immediate medical attention or contact a poison control center. Treatment is supportive and symptomatic; Cefdiren can be removed by hemodialysis if clinically necessary. Do not attempt home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture, in a tightly closed, light-resistant container. Keep Cefdiren out of reach of children.

Pediatric use: The safety and efficacy of Cefdiren in children under 12 years of age have not been established; it is approved for use in adults and adolescents 12 years and older.

Geriatric use: No overall differences in safety or effectiveness of Cefdiren have been observed between elderly and younger patients, but elderly patients are more likely to have reduced renal function, so renal status should be assessed and dosing adjusted accordingly.

Renal impairment: Dose reduction of Cefdiren is required based on creatinine clearance (see Dosage and Administration).

Hepatic impairment: No specific dose adjustment established; use with caution.

Carnitine deficiency risk groups: Patients with known or suspected carnitine deficiency or inborn errors of metabolism should not use Cefdiren (see Contraindications).

Duration of treatment with Cefdiren depends on the indication: 14 days for community-acquired pneumonia, 10 days for acute bacterial exacerbation of chronic bronchitis, pharyngitis/tonsillitis, and skin/skin-structure infections. The full course should be completed as prescribed, even if symptoms improve earlier, and courses should not be extended beyond what is prescribed due to the risk of carnitine depletion with prolonged use.

Third-generation (extended-spectrum) oral cephalosporin antibiotic; beta-lactam antibiotic class.

Cefditoren inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting the transpeptidation cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, causing osmotic instability and bacterial cell lysis, resulting in a bactericidal effect.

B

The safety and efficacy of Cefdiren have not been established in pediatric patients younger than 12 years. In adolescents 12 years of age and older, Cefdiren is dosed the same as in adults (200–400 mg twice daily depending on indication). Cefdiren should not be used in children with known or suspected carnitine deficiency or inborn errors of metabolism.